Truist Financial analyst Richard Newitter maintained a Hold rating on Nevro Corp (NVRO – Research Report) on May 10 and set a price target of $11.00. The company’s shares closed last Friday at $9.79.
According to TipRanks, Newitter is a 5-star analyst with an average return of 15.9% and a 58.50% success rate. Newitter covers the Healthcare sector, focusing on stocks such as Intuitive Surgical, Teleflex, and Nevro Corp.
The word on The Street in general, suggests a Hold analyst consensus rating for Nevro Corp with a $16.00 average price target, implying a 63.43% upside from current levels. In a report released on May 8, Robert W. Baird also reiterated a Hold rating on the stock with a $12.00 price target.
NVRO market cap is currently $359.6M and has a P/E ratio of -4.29.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nevro Corp (NVRO) Company Description:
Nevro Corp. engages in the provision of medical devices. The firm focuses on providing products that improve the quality of life of patients suffering from debilitating chronic pain. It develops and commercializes senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company was founded by Konstantinos Alataris in March 2006 and is headquartered in Redwood City, CA.
Read More on NVRO:
